T1	PROC 45 76	Estudio de eficacia y seguridad
T2	CHEM 80 89	ianalumab
T3	LIVB 93 102	pacientes
#1	AnnotatorNotes T3	C0030705; Patients; Patient or Disabled Group
T4	PROC 115 123	tratados
T7	PROC 203 250	Estudio de fase III, aleatorizado y doble ciego
T8	PROC 264 298	evalúan la eficacia y la seguridad
T9	CHEM 302 311	ianalumab
T10	CHEM 313 319	VAY736
T11	PROC 330 337	placebo
#4	AnnotatorNotes T11	C0032042; Placebos; Therapeutic or Preventive Procedure
T12	LIVB 341 350	pacientes
#5	AnnotatorNotes T12	C0030705; Patients; Patient or Disabled Group
T13	DISO 355 409	anemia hemolítica autoinmune por anticuerpos calientes
T14	DISO 411 416	AHAIc
T15	PROC 466 477	tratamiento
#6	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	DISO 500 554	Anemia hemolítica autoinmune por anticuerpos calientes
T17	DISO 556 561	AHAIc
T18	Age 591 598	18 años
T19	Age 607 612	o más
T20	PROC 636 650	consentimiento
T21	LIVB 654 667	Participantes
T23	PROC 759 790	prueba de antiglobulina directa
T25	DISO 891 898	recaído
T26	PROC 932 943	tratamiento
#7	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	LIVB 959 968	pacientes
#8	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T28	DISO 986 997	dependencia
#9	AnnotatorNotes T28	C0439857; Dependence; Mental or Behavioral Dysfunction | C1510472; Drug Dependence; Mental or Behavioral Dysfunction
T29	DISO 1000 1012	intolerancia
T30	CHEM 1019 1029	esteroides
#10	AnnotatorNotes T30	C0038317; Steroids; Organic Chemical · Pharmacologic Substance
T31	PROC 1033 1061	Concentración de hemoglobina
T32	DISO 1115 1123	síntomas
#11	AnnotatorNotes T32	C1457887; Symptoms; Sign or Symptom
T33	DISO 1144 1150	anemia
#12	AnnotatorNotes T33	C0002871; Anemia; Disease or Syndrome
T34	PROC 1167 1189	tratamiento de soporte
T35	Duration 1215 1233	al menos 4 semanas
T36	PROC 1246 1260	aleatorización
#13	AnnotatorNotes T36	C0034656; Randomization; Research Activity
T37	Speculated 1268 1290	criterios de inclusión
T38	PROC 1305 1314	protocolo
#14	AnnotatorNotes T38	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T39	Spec_cue 1315 1321	pueden
T40	LIVB 1358 1367	Pacientes
#15	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T42	DISO 1391 1414	enfermedad hematológica
#16	AnnotatorNotes T42	C0018939; Hematological Disease; Disease or Syndrome
T43	ANAT 1431 1442	médula ósea
#17	AnnotatorNotes T43	C0005953; Bone Marrow; Tissue
T44	DISO 1457 1460	LLC
#18	AnnotatorNotes T44	C0023434; Chronic Lymphocytic Leukemia; Neoplastic Process
T45	DISO 1469 1492	enfermedad inmunológica
#19	AnnotatorNotes T45	C0021053; Immune System Diseases; Disease or Syndrome
T46	PROC 1506 1535	tratamientos inmunosupresores
T47	Neg_cue 1540 1542	no
T48	Negated 1549 1559	permitidos
T49	DISO 1608 1612	AHAI
#20	AnnotatorNotes T49	C0002880; Autoimmune hemolytic anemia; Disease or Syndrome
T51	DISO 1647 1664	síndrome de Evans
#21	AnnotatorNotes T51	C0272126; Evans syndrome; Disease or Syndrome
T52	DISO 1673 1683	citopenias
#22	AnnotatorNotes T52	C0010828; Cytopenia; Pathologic Function
T53	PROC 1703 1736	terapia de depleción de células B
T54	CHEM 1743 1752	rituximab
#23	AnnotatorNotes T54	C0393022; rituximab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T56	PROC 1793 1807	aleatorización
#24	AnnotatorNotes T56	C0034656; Randomization; Research Activity
T57	PROC 1811 1822	Neutrófilos
T58	PROC 1836 1853	Creatinina sérica
#25	AnnotatorNotes T58	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
T59	DISO 1909 1941	Infecciones víricas, bacterianas
T61	DISO 1983 1995	tuberculosis
#27	AnnotatorNotes T61	C0041296; Tuberculosis; Disease or Syndrome | C0041327; Tuberculosis, Pulmonary; Disease or Syndrome
T62	LIVB 1998 2008	SARS-CoV-2
#28	AnnotatorNotes T62	C5203676; SARS-CoV-2; Virus
T63	PROC 2024 2045	tratamiento sistémico
T64	DISO 2095 2106	infecciones
#29	AnnotatorNotes T64	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T65	DISO 2160 2183	infecciones bacterianas
#30	AnnotatorNotes T65	C0004623; Bacterial Infections; Disease or Syndrome
T68	DISO 2233 2256	virus de la hepatitis C
T69	PROC 2258 2298	antígeno de superficie de la hepatitis B
#32	AnnotatorNotes T69	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T70	PROC 2300 2305	HBsAg
#33	AnnotatorNotes T70	C0201477; Hepatitis B surface antigen measurement; Laboratory Procedure
T71	PROC 2309 2348	anticuerpo del núcleo de la hepatitis B
T72	PROC 2350 2355	HBcAb
T73	DISO 2386 2425	inmunodeficiencia primaria o secundaria
T74	PROC 2445 2449	test
#34	AnnotatorNotes T74	C0022885; Laboratory Procedures; Laboratory Procedure
T75	DISO 2462 2498	virus de la inmunodeficiencia humana
T76	DISO 2500 2503	HIV
T77	CHEM 2508 2533	Vacunas vivas o atenuadas
T79	PROC 2572 2586	aleatorización
#35	AnnotatorNotes T79	C0034656; Randomization; Research Activity
T80	PROC 2602 2615	esplenectomía
#36	AnnotatorNotes T80	C0037995; Splenectomy; Therapeutic or Preventive Procedure
T84	PROC 2659 2668	protocolo
#37	AnnotatorNotes T84	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T85	Spec_cue 2669 2675	pueden
T86	Date 12 16	2022
T5	DISO 128 182	anemia hemolítica autoinmune por anticuerpos calientes
T22	PROC 792 795	PAD
T24	PROC 797 832	específica para anti-IgG o anti-IgA
T41	DISO 1372 1377	AHAIc
T87	DISO 1638 1644	mixtas
T50	DISO 1618 1635	anticuerpos fríos
T88	PROC 1568 1575	estudio
T60	LIVB 2188 2211	organismos encapsulados
T89	DISO 1950 1961	infecciones
T6	DISO 672 677	AHAIc
T90	DISO 973 984	resistencia
T55	Duration 1766 1776	12 semanas
T66	Speculated 2676 2683	aplicar
T78	Duration 2546 2555	4 semanas
T67	Route 2036 2045	sistémico
